Moderna (NASDAQ:MRNA) Hits New 12-Month Low – Time to Sell?

Moderna, Inc. (NASDAQ:MRNA) hit a new 52-week low during trading on Monday . The stock traded as low as $31.66 and last traded at $31.97, with a volume of 7440859 shares trading hands. The stock had previously closed at $32.60.

Wall Street Analyst Weigh In

A number of analysts recently commented on MRNA shares. Berenberg Bank boosted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Argus cut Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. reduced their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price on the stock. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $66.89.

Moderna Stock Down 1.3 %

The stock has a fifty day moving average of $39.53 and a two-hundred day moving average of $56.11. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a market cap of $11.75 billion, a price-to-earnings ratio of -5.25 and a beta of 1.59.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 2,664 shares of company stock worth $115,210 in the last three months. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MRNA. Norges Bank acquired a new stake in shares of Moderna in the fourth quarter valued at about $163,833,000. State Street Corp raised its holdings in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock worth $73,447,000 after acquiring an additional 1,113,455 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Finally, Amundi raised its stake in shares of Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after purchasing an additional 535,273 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.